Cascade Financial Partners, LLC Protalix Bio Therapeutics, Inc. Transaction History
Cascade Financial Partners, LLC
- $872 Billion
- Q3 2025
A detailed history of Cascade Financial Partners, LLC transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Cascade Financial Partners, LLC holds 17,000 shares of PLX stock, worth $31,620. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,000
Previous 17,000
-0.0%
Holding current value
$31,620
Previous $25.2 Million
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PLX
# of Institutions
82Shares Held
10.6MCall Options Held
23.6KPut Options Held
95.4K-
Opaleye Management Inc. Boston, MA2.58MShares$4.8 Million0.96% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.32MShares$2.45 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL902KShares$1.68 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA820KShares$1.52 Million0.0% of portfolio
-
Stratos Wealth Partners, Ltd.500KShares$930,0000.01% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $92.5M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...